Notwithstanding the noteworthy advances in its treatment, cancer remains one of the
most serious threatens to humans across the world. Hydroxamic acid derivatives, the potential inhibitors
of Histone Deacetylases (HDACs), could inhibit cancer cell proliferation, induce cell differentiation,
apoptosis and autophagy, and suppress angiogenesis, invasion as well as metastasis
through diverse signaling pathways. Thus, hydroxamic acid derivatives exhibit promising activity
against cancers and are useful scaffolds in modern anticancer drug discovery. The purpose of the
present review article is to summarize the recent developments (Jan, 2011-Jan, 2021) in hydroxamic
acid derivatives with insights into their in vivo anticancer potential and mechanisms of action.